SMARCA2 and lung adenocarcinoma: In terms of PFS, the results of the Kaplan–Meier analysis showed that SMARCA2-negative patients had poor PFS for NSCLC and lung adenocarcinoma, but there was no difference between the two groups for lung squamous cancer (Fig. 5 D, E, F).